Cascade is dedicated to liver and digestive diseases as well as inflammatory diseases. We focus on nuclear hormone receptors and GPCRs. With the corporate vision of "Making innovative medicines for hard-cured diseases and for prolonging human lives", we seek to become a new generation leader in global new drug development.

The R&D team of Cascade is jointly led by internationally renowned structural biologists and top scientists in the field of nuclear receptors. In the fields of metabolic diseases, tumors and inflammation targeting nuclear receptors, the R&D team has accumulated more than 20 years of innovative drug research and development. At the same time, it is a global leader in drug development and design based on protein crystal structure. The key members of Cascade team also have many years of management experience in international TOP10 pharmaceutical enterprises. Driven by a strong innovation foundation, Cascade has improved its preclinical R&D team and corresponding system platform of new drugs with excellent technology and standardized operation, including SPF animal facilities, pharmacochemical design and chemical synthesis platform, drug metabolism, pharmacological efficacy research platform and AI new drug research and development technology platform.